Damora TherapeuticsDMRA
Recorded

Damora Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration28 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Matt HagoodAnalyst

All right. Well, great. Thank you guys for being here. We are going to get started with our next session. My name is Matt Hagood. I am on the research team here at UBS, working with Mikey. We are excited to welcome our next presenting company, Damora Therapeutics, and we have the team here, guys. Thanks for being here. Maybe you want to give a quick introduction and then some background on Damora and the progress you have made this year and kind of the mutCALR space that you are working in. It would be great. Thanks.

Jennifer JarrettCEO

Yeah. Just quickly for introductions, I am Jen Jarrett, and I am the CEO of Damora.

Sherwin SattarzadehCOO

I am Sherwin Sattarzadeh today. I am the Chief Operating Officer.

Jennifer JarrettCEO

Background on Damora. We are a Fairmount company. We are actually the sixth company that was founded by Fairmount. I am sure you guys are familiar with a lot of the other Fairmount companies. I think they are up to like 11 or 12, or definitely double digits now. But we were founded specifically to focus on hematological diseases, and our initial focus is on the myeloproliferative neoplasm space. Myeloproliferative neoplasm is a group of blood cancers. The two that we are focusing on is essential thrombocythemia, which is when a patient produces too many platelets, and myelofibrosis, which is when a patient cannot produce healthy blood cells. And so these patients tend to be either anemic or neutropenic, et cetera.

Jennifer JarrettCEO

The specific mutation that we are focusing on is something called the CALR mutation, and it is a key driver of disease in patients with those two diseases, essential thrombocythemia and myelofibrosis. In fact, one-third of patients with those two diseases have this mutation. It is a very prevalent mutation, and there is about 45,000 patients in the U.S. alone that have that mutation. That translates into a TAM in the U.S. of over $10 billion. Our lead molecule is something called DMR-001. It was a molecule that was created by Paragon. For those of you that do not know Paragon is a company that is wholly owned by Fairmount. All they do is make antibodies. For most of the Fairmount companies that you know about, Oruka, Spyre, Apogee, et cetera, all of their antibodies came from this platform.

Jennifer JarrettCEO

This platform, I think, now has a very well-deserved reputation for creating best-in-class antibodies, and we believe that DMR-001 is also a best-in-class antibody. Like I said, DMR-001 targets the CALR mutation. As a result, it is blocking the key underlying cause of disease in patients that have this mutation. It just entered a phase I study a few months ago. The study is now open in Australia and the U.S. We are going to open in several other countries over the next few months. It is going to be a very big phase I/I-B study from a site perspective, and our goal, obviously, is to get the phase I in well as quickly as possible and to be able to start a phase III by the middle of 2028. We are very excited about what we are doing.

Jennifer JarrettCEO

We have a lot of questions, I know, that are teed up.

Jennifer JarrettCEO

Yeah Specifically about DMR-001, so I will stop there.

Matt HagoodAnalyst

Yeah, absolutely. No, it's We'll take questions.

Matt HagoodAnalyst

It's a really exciting space. Obviously, we just saw an acquisition yesterday from another mutCALR program, so there's a lot of investor enthusiasm in the space. I wanted to ask if you could talk a little bit about what we've seen so far from mutCALR-directed drugs that kind of validates this as a target across different indications, and yeah, we can go from there.

Jennifer JarrettCEO

Yeah. Stepping back in time, in ASH 2022, which was when the first presentation was made at a major medical meeting on this target, at that meeting, Incyte presented preclinical data for their antibody that targets the CALR mutation. This was an oral presentation to a packed audience, and it was the first time that a preclinical data presentation got an oral at ASH. So it made a huge splash, and what they showed there was obviously just preclinical data validating this pathway and the fact that this is a very important pathway with a very large percentage of patients with MPNs. Then in 2025 was when they presented their first initial clinical data at EHA. Stepping back to ASH, it was when Paragon saw that preclinical data at ASH that they recognized the two major liabilities with INCA033989.

Jennifer JarrettCEO

First was that it had a very suboptimal PK profile, which resulted in a very short half-life. That is why that drug needs to be given every two weeks by IV administration. The second major liability that they identified was that while their drug bound well to the type 1 mutation, which is one of the types of mutations with patients that have mutCALR, it did not bind nearly as well to the type 2 mutation. That has played out in the clinic. Going back to the data that was presented at EHA in 2025, this was the first data set that was presented in essential thrombocythemia, and the data looked very, very good in type 1 patients, but much less active in patients with type 2 disease. Exactly what you expected to see based on the preclinical data.

Jennifer JarrettCEO

That said, there was so much excitement around this data presentation that Incyte actually experienced an $8 billion increase in market cap just based on this data presentation at EHA in the middle of 2025, which just shows how much potential people saw in this class of therapies. What they are now showing is about an 80% response rate in type 1 patients with ET, but only about a 50% response rate in patients with type 2 disease. In myelofibrosis, they are seeing a similar pattern where they are seeing about half the response rates in patients with the type 2 mutation relative to patients with the type 1 mutation. As I mentioned earlier, they are also having to administer their drug every two weeks by IV administration, and we have a much better form of administration.

Jennifer JarrettCEO

The Incyte data is what has convinced everybody that this is a very validated and a very effective pathway. The other thing that they have shown is this is a very well-tolerated mechanism. Patients are staying on drug for very long periods of time. In the case of the ET data set in particular, they are really seeing no AEs that stand out, so that is another thing that people really like about this class of therapies. But that is the data set that, like I said, has convinced everybody that this is a very promising class of therapies for the treatment of these diseases.

Matt HagoodAnalyst

Perfect. You guys are in phase I now. I want to talk about the phase I study and design, eventually what you are going to show mid-year next year. But first, could you just talk about the design of your drug, how it is different from the Incyte molecule, and what you have done to kind of make this an optimal and how our drug could therapy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day